A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
A legfontosabb adatok
- Ki végzi
- Ascendis Pharma Bone Diseases A/S
- Hol
- Chicago, Greeley, Greenville, Houston, Minneota, New Brunswick, New York, Reno és Spokane Valley (Egyesült Államok)Mind a 9 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 36 fő, tervezett
- Kezdés
- 2026. máj. 7.
- Várható befejezés
- 2028. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Palopegteriparatide Experimental Arm
- Palopegteriparatide Control Arm
- A regiszteradat frissítve
- 2026. november 5.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Males and females, ≥18 years of age at the time of providing informed consent
- Participants with postsurgical chronic hypoparathyroidism (HP), or auto-immune, genetic, or idiopathic HP, for at least 26 weeks
- Receiving doses of palopegteriparatide at or above 30 µg/day; For individuals receiving 30 µg/day: evidence that dose is insufficient to keep serum calcium in the normal range, defined as:; Documented hypocalcemia within 12 weeks prior to Screening; and/or Standing dose of calcitriol ≥0.25 μg/day, and / or (elemental) calcium ≥1500 mg/day (e.g., calcium citrate, calcium carbonate etc.) for at least 4 weeks prior to Screening; For individuals receiving 33 µg/day or greater: no requirement for documented hypocalcemia or minimum doses of calcitriol or elemental calcium
- Confirmation of laboratory parameters (Central or Local) within 2 weeks of screening visit and prior to randomization:; 25(OH) vitamin D levels of ≥ 20 ng/mL (≥49 nmol/L) and Magnesium level in the normal range, or just below the normal range i.e.: ≥1.3 mg/dL (≥0.53 mmol/L) and Albumin-adjusted or ionized sCa level in the normal range or just below the normal range
- Albumin-adjusted sCa 7.8 - 10.6 mg/dL (or 1.95 - 2.64 mmol/L)
- Ionized sCa 4.40 - 5.29 mg/dL (1.10 - 1.32 mmol/L); BMI 17- 40 kg/m2 at Screening; If ≤25 years of age, radiological evidence of epiphyseal closure based on locally interpreted X-ray of non-dominant wrist and hand; eGFR ≥30 mL/min/1.73 m2 during Screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
Ki nem vehet részt
- Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1
- Use of PTH-like drugs other than palopegteriparatide (whether commercially available or through participation in an investigational trial), including PTH(1-34), or other N-terminal fragments, analogs of PTH or PTH-related protein, or PTH1R biased agonists within 4 weeks prior to Screening
- Use of denosumab or romosozumab within 2 years prior to Screening. Use of raloxifene within 4 weeks prior to Screening
- Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening
- Diagnosed drug or alcohol dependence within 3 years prior to Screening
- Chronic or severe cardiac disease within 26 weeks prior to Screening
- Cerebrovascular accident within 5 years prior to Screening
- Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout
- Participation in any other interventional trial in which receipt of investigational drug or device other than palopegteriparatide occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug) (whichever comes first) prior to Screening
- Known allergy or sensitivity to PTH or any of the excipients [metacresol, mannitol, succinic acid, NaOH/(HCl)] of the investigational product
- Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP
- Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin >30 µg/day, or systemic corticosteroids (other than as replacement therapy)
- Use of drugs known to influence calcium and bone metabolism within 12 weeks prior to Screening
- Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
- Increased risk for osteosarcoma
- Women who are pregnant, intend to become pregnant, or are lactating
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Chicago, IllinoisHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
- Greeley, ColoradoHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
- Greenville, North CarolinaHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
- Houston, TexasHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
- Minneota, MinnesotaHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
- New Brunswick, New JerseyHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
- New YorkHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
- Reno, NevadaHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
- Spokane Valley, WashingtonHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.
A vizsgálat 2 csoportja
- Palopegteriparatide Experimental ArmA vizsgált kezelés
Palopegteriparatide administered once daily by subcutaneous injection and titrated to an optimal dose by a novel titration algorithm.
- Palopegteriparatide Control ArmMár használt kezelés, összehasonlításként
Palopegteriparatide administered once daily by subcutaneous injection and titrated to an optimal dose by a previously evaluated titrated algorithm
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
- A regiszteradat frissítve
- 2026. november 5.